共 50 条
- [48] A SINGLE DOSE OF GEMTUZUMAB-OZOGAMICIN (GO) IN CONSOLIDATION PRIOR TO AUTOLOGOUS TRANSPLANT FOR YOUNGER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID (AML) IS SAFE BUT HAS NO EFFECT ON DISEASE FREE SURVIVAL: INTERIM RESULTS OF EASTERN COOPERATIVE ONCOLOGY GROUP STUDY (E1900) BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 21 - 22
- [50] Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia:: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups LEUKEMIA, 2005, 19 (10) : 1768 - 1773